Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3285-3292

  Kim, Jeonga ^a   Park, Hyeyoung ^a   Ji, Young Im ^a   Wahn, Soo Choi ^b   Hyung, Sik Kim ^a  

^a Pusan National University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Androgen receptor; Cell cycle arrest; Histone deacetylase inhibitor; Prostate cancer; Sodium butyrate

Indexed keywords

ANDROGEN RECEPTOR; BUTYRIC ACID; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4;

ACETYLATION; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ACETYLATION; ANDROGENS; BUTYRATES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; HISTONES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 35348966849     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, Ahn YO, Shin MH, Lee CW, Lee DH, Blair A, Devesa SS and Hsing AW: Rising prostate cancer rates in South Korea. Prostate 66: 1285-1291, 2006.
2. Korea National Statistical Office, Korean Statistical Information System (KOSIS), Annual report on the cause of death statistics, 1983-2003. Seoul, Korea, 2005. [http://kosis.nso.go.kr:7001/ups/chapterRetrieve.jsp?pubcode= MA&seq=241&pub=3]
3. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G and Klocker H: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35: 63-70, 1998.
4. Wang LG, Liu XM, Kreis W and Budman DR: Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 259: 21-28, 1999.
5. Kang Z, Janne OA and Palvimo JJ: Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 18: 2633-2648, 2004.
6. Miyamoto H, Messing EM and Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61: 332-353, 2004.
7. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL and Visakorpi T: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555, 2001.
8. Agoulnik IU and Weigel NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99: 362-372, 2006.
9. Zegarra-Moro OL, Schmidt LJ, Huang H and Tindall DJ: Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013, 2002.
10. Monneret C: Histone acetylase inhibitors. Eur J Med Chem 40: 1-13, 2005
11. Roy S, Packman D, Jeffrey R and Tenniswood M: Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491, 2005.
12. Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim TY, Kim NK and Bang YJ: Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 26: 3429-3438, 2006.
13. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W and Chiao JW: Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res 26: 1225-1230, 2006.
14. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC and Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10: 8094-8104, 2004.
15. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I and Kamada H: Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2 related protein bad. Brain Tumor Pathol 18: 109-114, 2001.
16. Jung JW, Cho SD, Ahn NS, Yang SR, Park JS, Jo EH, Hwang JW, Jung JY, Kim SH, Kang KS and Lee YS: Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate. Cancer Lett 225: 199-206, 2005.
17. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133: 2485S-2493S, 2003.
18. Kip1 protein levels is required of G1 arrest in fibroblasts. J Cell Physiol 202: 87-99, 2005.
19. Ouwehand K, de Ruijter AJ, van Bree C, Caron HN and van Kuilenburg AB: Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett 579: 1523-1528, 2005.
20. Abramova MV, Pospelova TV, Nikulenkov FP, Hollander CM, Fornace AJ Jr and Pospelov VA: G1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of β-catenin. J Biol Chem 281: 21040-21051, 2006.
21. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S and Ragno R: Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261-309, 2005.
22. WAF1/CIP1 is dispensable for G1 arrest but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 23: 21-29, 2004.
23. Finzer P, Kuntzen C, Soto U, zur Hausen H and Rosi F: Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20: 4768-4776, 2001.
24. Boutillier AL, Trinh E and Loeffler JP: Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 84: 814-828, 2003.
25. WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett 570: 37-40, 2004.
26. Caldon CE, Daly RJ, Sutherland RL and Musgrove EA: Cell cycle control in breast cancer cells. J Cell Biochem 97: 261-274, 2006.
27. Waf1/Cip1. Mol Cell Biol 26: 2782-2790, 2006.
28. Burnstein KL: Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95: 657-669, 2005.
29. Korkmaz CG, Fronsda K, Zhang Y, Lorenzo PI and Saatcioglu F: Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J Endocrinol 182: 377-389, 2004.
30. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F and Ringert RH: Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24: 25-31, 2004.
31. Gaughan L, Logan IR, Neal DE and Robson CN: Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33: 13-26, 2005.
32. Rokhin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG and Cohen MB: Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 4: 113-123, 2006.
33. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M and Rodriguez R: Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 66: 7237-7244, 2006.
34. Kim J and Coetzee GA: Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93: 233-241, 2004.
35. Sang Y, Myers M and Brown M: Formation of the androgen receptor transcription complex. Mol Cell 9: 601-610, 2002.
36. Yeung LH, Read JT, Sorenson P, Nelson CC, Jia W and Rennte PS: Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter. Biochem J 371: 843-855, 2003.
37. Lu S, Liu M, Epner DE, Tsai SY and Tsai MJ: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13: 376-384, 1999.
38. WAF1 expression via ATM. Cancer Res 63: 2891-2897, 2003.
39. Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24: 5606-5618, 2005.
40. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol Mateo M, Miluendas R, Camacho F, Sanchez-Aguilera A, Sanchez E and Piris MA: Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159: 205-213, 2001.
41. Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH and Qiu DK: Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol 10: 2643-2646, 2004.
42. CIP1/WAF1 induction. Mol Cell Biochem 285: 51-59, 2006.